Head-To-Head Review: CERo Therapeutics (CERO) & The Competition

CERo Therapeutics (NASDAQ:CERO) is one of 248 public companies in the “MED – DRUGS” industry, but how does it weigh in compared to its rivals? We will compare CERo Therapeutics to similar companies based on the strength of its valuation, dividends, risk, profitability, earnings, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and target prices for CERo Therapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1	3	0	0	1.75
CERo Therapeutics Competitors	2205	3796	9846	410	2.52

CERo Therapeutics currently has a consensus price target of $45.00, indicating a potential upside of 47,772.34%. As a group, “MED – DRUGS” companies have a potential upside of 57.99%. Given CERo Therapeutics’ higher probable upside, research analysts clearly believe CERo Therapeutics is more favorable than its rivals.

Institutional & Insider Ownership

29.6% of CERo Therapeutics shares are owned by institutional investors. Comparatively, 44.1% of shares of all “MED – DRUGS” companies are owned by institutional investors. 12.7% of CERo Therapeutics shares are owned by insiders. Comparatively, 13.6% of shares of all “MED – DRUGS” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares CERo Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
CERo Therapeutics Competitors	-20,892.98%	-168.28%	-17.95%

Risk & Volatility

CERo Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, CERo Therapeutics’ rivals have a beta of -0.74, indicating that their average share price is 174% less volatile than the S&P 500.

Earnings & Valuation

This table compares CERo Therapeutics and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
CERo Therapeutics	N/A	-$8.30 million	0.00
CERo Therapeutics Competitors	$1.08 billion	$58.56 million	2.83

CERo Therapeutics’ rivals have higher revenue and earnings than CERo Therapeutics. CERo Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

CERo Therapeutics rivals beat CERo Therapeutics on 9 of the 13 factors compared.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.